SCHEDULE: Major Shareholder Boosts Caris Life Sciences Stake

David D. Halbert and Caris Halbert, L.P. disclose significant beneficial ownership, collectively holding 44.1% of Caris Life Sciences, Inc. common stock.

Summary

• David D. Halbert, an officer, director, and beneficial owner, reported beneficial ownership of 124,906,296 shares of Caris Life Sciences, Inc. common stock, representing 44.1% of the class.
• Caris Halbert, L.P. reported beneficial ownership of 101,261,532 shares of Caris Life Sciences, Inc. common stock, representing 36.0% of the class.
• Mr. Halbert's sole voting and dispositive power covers 3,881,294 shares, which includes 1,881,294 directly held shares and options to purchase 2,000,000 shares.
• Shared voting and dispositive power for Mr. Halbert covers 121,025,002 shares (voting) and 121,025,022 shares (dispositive), encompassing shares held by Caris Halbert, L.P., ADAPT I Ltd., Carisome I, L.P., Caris Investment II Ltd, and Caris Investment III Ltd.
• Mr. Halbert is the managing member of Caris Investment Management, LLC, which is the general partner of Caris Halbert, L.P., Caris Investment II Ltd., and Caris Investment III Ltd., and also trustee of family trusts that are general partners of ADAPT I Ltd. and Carisome I, L.P.
• The percentages of common stock are based on 281,224,124 shares outstanding as of August 7, 2025, plus 218,794 shares issued to Mr. Halbert post-August 7, 2025.

Sentiment

Score: 6

Explanation: The filing indicates a substantial and continued beneficial ownership by key individuals and entities, suggesting long-term confidence in the company, which is generally viewed positively by the market, though it does not provide new operational or financial performance data.

Positives

• The significant beneficial ownership by David D. Halbert and related entities, totaling 44.1% of the common stock, indicates a strong, committed long-term interest from a key insider and major investor.
• The disclosure provides transparency regarding the ownership structure and control, which can be viewed positively by investors seeking clarity on major stakeholders.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding the company's future performance or strategic outlook.

Industry Context

This Schedule 13G filing indicates a significant, passive ownership stake in Caris Life Sciences, Inc., a company operating in the life sciences sector. Such a substantial holding by a key individual and related entities can signal long-term confidence in the company's prospects within the competitive and innovation-driven biotechnology and diagnostics industry.

Corporate Governance

Related Party Transactions

• The filing details that David D. Halbert, as managing member of Caris Investment Management, LLC (general partner of Caris Halbert, L.P., Caris Investment II Ltd., and Caris Investment III Ltd.) and trustee of two family trusts (general partners of ADAPT I Ltd. and Carisome I, L.P.), has voting and investment power over shares held by these entities. This establishes a clear related-party control structure over a significant portion of the company's shares.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant ownership stakes and the control structure, potentially signaling stability and long-term commitment from a major investor.
• Regulatory Bodies: Ensures compliance with SEC disclosure requirements for beneficial ownership, enhancing market transparency.

Next Steps

• Continued compliance with SEC filing requirements for beneficial ownership disclosures (e.g., Schedule 13D/G amendments as ownership changes).

Key Dates

Recommendation

This Schedule 13G filing primarily discloses beneficial ownership and does not contain financial performance data, strategic updates, or forward-looking guidance that would warrant a change in investment recommendation. It confirms a significant, passive stake by key individuals and related entities, which is a neutral to slightly positive signal of long-term commitment, but insufficient to alter an investment thesis.

Keywords

Caris Life Sciences, David D. Halbert, Caris Halbert L.P., Schedule 13G, beneficial ownership, common stock, SEC filing, institutional investor, passive investment, biotechnology